Los anti-5HT3: Un nuevo grupo de antieméticos

Revista Clinica Espanola

Volumn 196, Issue 2, 1996, Pages 119-124

  Carrion Galindo J R ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; GRANISETRON; IFOSFAMIDE; LOMUSTINE; METOCLOPRAMIDE; MITOMYCIN; ONDANSETRON; PROCARBAZINE; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; TROPISETRON;

DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; HEADACHE; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; PROGNOSIS; RASH; REVIEW; VOMITING;

ADULT; ANTIEMETICS; GRANISETRON; HUMANS; INDOLES; ONDANSETRON; SEROTONIN ANTAGONISTS; TIME FACTORS;

EID: 0013455623     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Borison H, McCarthy L. Neuropharmacology of chemotherapy induced emesis. Drugs 1983, 25 (suppl 1).8-17.
2. Miner W, Sanger G, Turner D. Evidence that 5-hydroxytryptamine 3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer 1987, 56:159-162.
3. Andrews P, Rapeport W. Sanger G. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988: 9:334-341.
4. Barnes N, Ge J, Jones W, Naylor R, Rudd J. Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine. Br J Cancer 1990; 62:862-864.
5. Cubeddu L, Horffman I, Fuenmayor N, Finn A. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322:810-816
6. Grunberg S, Hesketh P. Control of chemotherapy-induced emesis. N Engl J Med 1993; 329:1.790-1.796
7. Martin M, Diaz-Rubio E. Emetogenicidad de los citotóxicos. Evaluacion del curso espontáneo de la emesis inducida por cisplatino, carboplatino y la combinación FAC. En: Rosell R, ed. Tratamiento con metoclopramida de la emesis inducida por la quimioterapia antineoplásica. Badalona. Jarpyo, SA, 1991; 41-51
8. Barnadas A, Moreno I. Factores pronósticos que influyen en la prevención de la emesis inducida por citostáticos. En: Rosell R. ed. Tratamiento con metoclopramida de la emesis inducida por la quimioterapia antineoplásica Badalona: Jarpyo, SA, 1991; 52-72.
9. Chacón J, Gonzalez M. Emesis inducida por la quimioterapia antineoplásica. Factores pronósticos. En: Gonzalez Baron M, Ordóñez A. García de Paredes M, Feliu J, Zamora P, Espinosa E, eds. Factores pronósticos en oncologia. Madrid- Interamericana McGraw-Hill, 1994; 514-527.
10. Pater J, Willan A. Methodologic issues in trials of antiemetics. J Clin Oncol 1984; 2:484-487
11. Rosell R. Abad Esteve A, Moreno Solarzano I. Métodos de evaluación clínica de antieméticos. Rev Cancer (Madrid) 1989; 3:114-119.
12. Tonato M, Roila F, De Favero A Methodology of antiemetic trials. a review. Ann Oncol 1991; 2:107-114
13. Willan A, Warr D, Pater J, Levitt M. Erlichman C. Osoba D. Methodological issues in antiemetic studies. En: Osoba D, ed. Effect of cancer on quality of life. Boca Ratón: CRC Press, 1991; 229-249.
14. Gordon McVie J, de Bruijn K. Methodology of antiemetic trials. Drugs 1992; 43 (suppl 3): 1-5
15. Rosell Costa R Estudios aleatorios de fármacos antieméticos: necesidad de establecer el criterio de dosis Optima para su correcta comparación de eficacia. Rev Clin Esp 1991, 188:117-119.
16. Olver I, Matthews J, Bishop J. Smith R. The roles of patient and observer assessment in anti-emetic trials. Eur J Cancer 1994; 30A: 1.223-1.227.
17. Herrstedt J We still need commom criteria for the assessment of nausea and vomiting. Eur J Cancer 1994; 30A: 1.217.
18. Franklin H, Simonetti G, Dubbelman A, et al. Toxicity grading systems. A comparison between the WHO scoring system and the commom toxicity criteria with used for nausea and vomiting. Ann Oncol 1994; 5:113-117.
19. Dilly S. Are granisetron and ondansetron equivalent in the clinic? Eur J Cancer 1992; 28A (suppl 1):S32-S35
20. Olver I. Antiemetic study design, desirable objectives, stratifications and analyses. Br J Cancer (suppl) 1992. 19 S30-S33.
21. Senn S. The AB/BA crossover, past, present and future? Stat Meth Med Res 1994: 3:303-324.
22. Gralla R Antiemetic therapy. En: DeVita V. Heliman S. Rosenberg S. eds. Cancer: principles & practice of oncology. Philadelphia: JB Lippincott Co . 1993; 2.338-2.348
23. Diehl V, Marty M Efficacy and safety of antiemetics. Cancer Treat Rev 1994: 20:379-392
24. The Medical Letter. Fármacos para los vómitos provocados por la quimioterapia anticancerosa (ed española) 1994: 16:18-20
25. Kris M, Gralla R, Clark R, Tyson L, Groshen S. Antiemetic control and prevention of side-effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone: a double-bund randomized trial. Cancer 1987; 60.2.816-2.822.
26. Rosell R. Tratamiento con metoclopramida de las náuseas y vómitos secundarios a la quimioterapia. En: Rosell R. ed. Tratamiento con metoclopramida de la emesis inducida por la quimioterapia antineoplásica. Badalona. Jarpyo, SA. 1991: 1-10.
27. Aapro M. «Setron»: are 5-HT3 receptor antagonists different? Eur J Cancer 1993; 29A: 1.655
28. Plosker G, Goa K. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 1991: 42:805-824.
29. Andrews P, Bhandari P, Davey P, Bingham S, Marr H, Blower P. Are all 5-HT3 receptor antagonists the same? Eur J Cancer 1992; 28A (suppl 1):S2-S6.
30. Yarker Y. McTavish D. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994; 48:761-793.
31. Chevalier B on behalf of the Granisetron Study Group. Efficacy and safety of granisetron compared with high-dose metocolopramide plus dexamethasone in patients receiving high-dose cispiatin in a single-blind study Eur J Cancer 1990; 26 (suppl 1):S33-S36.
32. Warr D, Wilan A, Venner P, et al. A randomized, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induce emesis. An NCl Canada Trials Group Phase III Trial. Eur J Cancer 1993; 29A:33-36
33. The Italian Group for antiemetic research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995: 332:1-5
34. Aapro M. Acute emesis: prevention with intravenous «setrons». Emesis control and beyond. Satellite Symposium. Abstract book. 19th ESMO Congress. Lisbon, 1994; 6-13.
35. Fujii Y, Tanaka H, Toyooka H. Reduction of postoperative nausea and vomiting with granisetron. Can J Anaesth 1994; 41:291-294.
36. The Medical Letter. Granisetron para prevenir los vómitos tras la quimioterapia anticancerosa (ed. española) 1994; 16:81-82.
37. Riviere A on behalf of the Granisetron Study G Dose finding of granisetrron in patients receiving high-dose cispiatin chemotherapy Br J Cancer 1994; 69:967-971.
38. Navari R, Kaplan H, Gralla R, Grunberg S, Palmer R, Fitts D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cispiatin. J Clin Oncol 1994; 12:2.204-2.210.
39. Pérez E. Acute emesis: can oral treatment match i v.? Emesis control and beyond. Satellite Symposium. Abstract book. 19th ESMO Congress. Lisbon, 1994; 18-25.
40. Heron J, Goedhals L, Jordaan J, Cunningham J, Cedar E on behalf of the Gransietron Study Group. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis Ann Oncol 1994, 5:579-584
41. Milne R, Heel R, Ondansetron. Therapeutic use as an antiemetic. Drugs 1991: 41:574-595.
42. Bleiberg H. Antiemetic agents, Curr Opin Oncol 1992, 4 597-604
43. Markham A, Sorkin E. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting Drugs 1993: 45 931-952.
44. Sledge GJ, Einhorn L, Nagy C, House K Phase III double-blind comparison of intravenous Ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy Cancer 1992; 70:2.524-2 528.
45. Italian Group for antiemetic research. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy J Clin Oncol 1993, 11:2.396-2.404
46. Bonneterre J. Chevallier B, Metz R, et al. A randomized double-blind comparison of Ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy J Clin Oncol 1990; 8:1 063-1 069.
47. Kaasa S, Kvaloy S, Dicato M, Ries F, Huys J, Royer E A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy induced nausea and vomiting: a randomized, double-blind study Eur J Cancer 1990: 26 311-314
48. Levitt M, Warr D, Yelle L, et al. Ondansetron compared with dexamethasone and metocolopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate and fluorouracil. N Engl J Med 1993, 328:1.081-1.084.
49. Kris M, Baltzer L, Pisters K, Tyson L. Enhancing the effectiveness of the specific serotonin antagonists Combination antiemetic therapy with dexamethasone. Cancer 1993. 72 (suppl 11) 3.436-3 442
50. Joss R, Bacchi M, Buser K, et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients, Ann Oncol 1994; 5:253-258.
51. Hesketh P, Harvey W, Harvey W, et al. A randomized, doubte-biind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12:596-600
52. Spitzer T, Bryson J, Cirenza E, et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation J Clin Oncol 1994; 12:2.432-2.438.
53. Gandara D, Harvey W, Monaghan G, Pérez E, Hesketh P. Delayed emesis following high-dose cisplatin: a double-blind randomized comparative trial of ondansetron [GR 38032F) versus placebo Eur J Cancer 1993: 29A (suppl 1)S35-S38.
54. Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer institute of Canada Clinical Trials Group J Can Oncol 1994; 12:1.050-1.057.
55. De Mulder P. Delayed emesis: is there a role for 5-HT3 antagonists? Emesis control and beyond. Satellite Symposium. Abstract book. 19th ESMO Congress Lisbon, 1994; 26-31.
56. De Bruijn K. Tropisetron. A review of the clinical experience. Drugs 1992: 43 (suppl 3):11-22.
57. Rhoda Lee C, Plosker G, McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as an antiemetic. Drugs 1993, 46:925-943.
58. Sorbe B, Hogberg T, Glimelius B, et al. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer 1994, 73:445-454.
59. Sorbe B, Hogberg T, Himmelmann A, et al. Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by asplatin-containing chemotherapy. Eur J Cancer 1994; 30A:629-634.
60. Hulstaert F, Van Belle S, Bleiberg H, et al. Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting. J Clin Oncol 1994; 12-2.439-2.446.
61. Suárez A, Stettler E, Rey E, et al. Safety, tolerability, efficacy and plasma concentrations of tropisetron after administration at five dose levels to children receiving cancer chemotherapy Eur J Cancer 1994; 30A: 1.436-1.441.
62. Sorbe B, Berglind A, de Bruijn K, Tropisetron, a new 5-HT3 receptor antagonist in the prevention of radiation-induced emesis. Radiother Oncol 1992, 23.131-132.
63. Zomers P, Langenberg C, de Bruijn K. Tropisetron for postoperative nausea and vomiting in patients after gynaecological surgery. Br J Anaesth 1993; 71:677-680.
64. Van Belle S, Stamatakis L, Bleiberg H, Cocquyt V, Michel J, de Bruijn K. Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol 1994; 5:821-825
65. Jantunen I, Muhonen T, Kataja V, Flander M, Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy-a randomized study. Eur J Cancer 1993; 29A: 1.669-1.672.
66. Noble A, Bremer K. Goedhals L. Cupissol D, Dilly S on behalf of the Granisetron Study Group. A double-blind, randomized, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference Eur J Cancer 1994; 30A; 1.083-1.088.
67. Gebbia V, Cannata G, Testa A. et al. Ondansetron uersus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer 1994; 74-1.945-1.952.
68. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomized, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 1994; 51-113-118.
69. Zammit-Lucia J. Modeling budgetary impact for decision makers. Anti-Cancer Drugs 1993; 4 (suppl 3):21-25
70. Kaye S, Khayat D, Aapro M, Diehl V. Who should receive a 5-HT3 antagonist? (letter) Lancet 1992; 340:1.107-1.108.
71. Gralla R. Current issues in the management of nausea and vomiting. Ann Oncol 1993; 4 (suppl 3);S3-S7.
72. Smyth J New directions for anti-emetic research (editorial). Ann Oncol 1994; 5.569-570.
73. Jones A, Lee G, Bosanquet N The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis. Eur J Cancer 1992; 29A:51-56.